Dual inhibition of Akt and cMET by the inhibitors MK2206 and capmatinib, respectively, could inhibit the proliferation of sorafenib-resistant HCC cells in vitro and sorafenib-resistant HCC xenografts in mice (Han et al., 2017). This evidence concerns the gene AKT1 and hepatocellular carcinoma.